MAQUET Cardiovascular Announces Results Of The IABP-SHOCK II Trial Of Intra-aortic Balloon Counterpulsation Therapy In Cardiogenic Shock Patients

MAQUET Cardiovascular Announces Results Of The IABP- SHOCK II Trial Of Intra-aortic Balloon Counterpulsation Therapy In Cardiogenic Shock Patients PR Newswire MUNICH and WAYNE, New Jersey, Aug. 27, 2012 --Study Results Demonstrating Trend Toward Improvement in 30-Day All-Cause Mortality Presented at ESC Congress 2012-- MUNICH and WAYNE, New Jersey, Aug. 27, 2012 /PRNewswire/ -- MAQUET Cardiovascular LLC, the market leader in intra-aortic balloon counterpulsation therapy, today announced 30-day results from the large, randomized, multicenter IABP- SHOCK II ("SHOCK II") clinical trial in patients with acute myocardial infarction (AMI) who were in cardiogenic shock and undergoing early revascularization. The findings showed that use of intra-aortic balloon counterpulsation (IABC) therapy was associated with an observed improvement in all-cause mortality at 30 days, but the trial did not meet the pre- specified 12 percent improvement in survival endpoint compared with standard medical therapy. In the trial, IABC therapy was shown to be safe without any increase in complications compared to the control group. The findings were presented in the Hot Line II: Late-Breaking Trials on Interventions session during the European Society of Cardiology (ESC) Congress 2012 in Munich. "Patients in cardiogenic shock are critically ill and require aggressive treatment measures," said Marc Cohen, M.D., chief of the division of cardiology at Newark Beth Israel Medical Center in Newark, N.J.